Alembic Pharmaceuticals has received final approval from the USFDA for its generic Carbamazepine extended-release tablets (100 mg, 200 mg, and 400 mg), used to treat seizures and nerve pain. The product is a generic version of Novartis’ Tegretol-XR. According to IQVIA, the U.S. market for these tablets is estimated at $71 million for the 12 months ending March 2025.